Milestone Asset Management LLC Buys Shares of 3,137 Medpace Holdings, Inc. $MEDP

Milestone Asset Management LLC bought a new stake in Medpace Holdings, Inc. (NASDAQ:MEDP) during the 4th quarter, Holdings Channel reports. The firm bought 3,137 shares of the company’s stock, valued at approximately $1,762,000.

Several other hedge funds and other institutional investors also recently modified their holdings of the stock. AQR Capital Management LLC grew its stake in shares of Medpace by 65.1% in the 3rd quarter. AQR Capital Management LLC now owns 1,025,410 shares of the company’s stock valued at $518,170,000 after purchasing an additional 404,226 shares during the last quarter. Wasatch Advisors LP grew its stake in shares of Medpace by 14.0% in the 2nd quarter. Wasatch Advisors LP now owns 945,814 shares of the company’s stock valued at $296,853,000 after purchasing an additional 116,354 shares during the last quarter. Baillie Gifford & Co. grew its stake in shares of Medpace by 12.0% in the 3rd quarter. Baillie Gifford & Co. now owns 584,796 shares of the company’s stock valued at $300,679,000 after purchasing an additional 62,503 shares during the last quarter. Invesco Ltd. grew its stake in shares of Medpace by 18.9% in the 3rd quarter. Invesco Ltd. now owns 537,407 shares of the company’s stock valued at $276,313,000 after purchasing an additional 85,517 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership grew its stake in shares of Medpace by 205.8% in the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 314,150 shares of the company’s stock valued at $161,523,000 after purchasing an additional 211,411 shares during the last quarter. 77.98% of the stock is currently owned by hedge funds and other institutional investors.

Key Medpace News

Here are the key news stories impacting Medpace this week:

• Positive Sentiment: Q1 EPS and revenue beat consensus — GAAP EPS $4.28 vs. $3.74 expected; revenue $706.6M, up 26.5% year/year. This confirms near‑term profit momentum. Medpace (MEDP) Q1 Earnings and Revenues Beat Estimates
• Positive Sentiment: Large backlog and revenue growth — backlog reported roughly $2.93B and FY revenue showed strong YoY growth, supporting medium‑term revenue visibility. Medpace Press Release (Q1 2026)
• Neutral Sentiment: Company reiterated FY2026 guidance — EPS range of 16.680–17.500 and revenue ~ $2.755–$2.855B (company range overlaps street estimates). Guidance kept outlook intact but the EPS range sits around street consensus, leaving little upside. Medpace Press Release (Guidance)
• Neutral Sentiment: Leadership note — President Jesse Geiger plans to retire effective May 31; CEO August Troendle will reassume the president role until a successor is named. This is organizationally manageable but introduces near‑term uncertainty. Medpace slides 20.8% as Q1 book-to-bill drops below 1 and president retirement is disclosed
• Negative Sentiment: Book‑to‑bill below 1.0 (0.88) — net new awards lagged recognized revenue in Q1, raising concerns about future top‑line momentum and prompting investors to mark down future growth expectations. Medpace slides 20.8% as Q1 book-to-bill drops below 1 and president retirement is disclosed
• Negative Sentiment: Multiple law firms and investor notices — several firms have announced class‑action filings/investigations tied to the company and the recent disclosures; that litigation risk can pressure the stock and increase uncertainty. ROSEN Law Firm Notice re: Medpace Securities Class Action
• Negative Sentiment: Notable insider selling history highlighted in reporting — heavy insider dispositions over recent months can weigh on investor sentiment even if not tied to a single event. Quiver Quantitative — insider and institutional activity

Medpace Price Performance

Medpace stock opened at $508.46 on Thursday. Medpace Holdings, Inc. has a 1-year low of $282.84 and a 1-year high of $628.92. The company has a market cap of $14.52 billion, a PE ratio of 33.23, a price-to-earnings-growth ratio of 2.43 and a beta of 1.39. The stock’s 50 day moving average price is $471.41 and its 200 day moving average price is $537.55.

Medpace (NASDAQ:MEDP) last posted its earnings results on Wednesday, April 22nd. The company reported $4.28 EPS for the quarter, topping analysts’ consensus estimates of $3.74 by $0.54. The company had revenue of $706.60 million for the quarter, compared to the consensus estimate of $697.82 million. Medpace had a return on equity of 118.82% and a net margin of 17.83%.Medpace’s quarterly revenue was up 26.5% compared to the same quarter last year. During the same period in the previous year, the business earned $3.67 earnings per share. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. On average, equities research analysts anticipate that Medpace Holdings, Inc. will post 17.05 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts have weighed in on the company. Truist Financial lowered their target price on Medpace from $555.00 to $539.00 and set a “hold” rating on the stock in a research note on Wednesday, February 11th. Leerink Partners lowered their target price on Medpace from $575.00 to $485.00 and set a “market perform” rating on the stock in a research note on Wednesday, February 11th. Weiss Ratings downgraded Medpace from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Monday, April 6th. Barclays upgraded Medpace from an “underweight” rating to an “equal weight” rating and set a $500.00 price target on the stock in a research note on Friday, March 6th. Finally, Zacks Research downgraded Medpace from a “strong-buy” rating to a “hold” rating in a research note on Monday, January 12th. Four research analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $486.67.

Insider Buying and Selling

In other Medpace news, President Jesse J. Geiger sold 31,707 shares of the business’s stock in a transaction on Tuesday, March 17th. The stock was sold at an average price of $455.30, for a total transaction of $14,436,197.10. Following the sale, the president directly owned 15,000 shares in the company, valued at approximately $6,829,500. The trade was a 67.88% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 20.50% of the company’s stock.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.